STATEMENT of the National Organization for Rare Disorders (NORD) at the U.S. Food and Drug Administration Part 15 Public Hearing - National Organization for Rare Disorders - Document - PDFSEARCH.IO - Document Search Engine

Back to Results

First Page	Meta Content
	STATEMENT of the National Organization for Rare Disorders (NORD) at the U.S. Food and Drug Administration Part 15 Public Hearing Add to Reading List Document Date: 2012-12-18 11:57:21 Open Document File Size: 179,20 KB Share Result on Facebook Company NORD / Amicus / / Country United States / / Facility Willard Hotel / / IndustryTerm pharmaceutical industry / each rare disorder therapy / rare disorder therapy / focus / drugs products / each particular rare disorder therapy / health care reform law / therapies for prevalent diseases / therapies for rare diseases / therapy for a rare disorder / treatment of rare disease / annual insurance caps / orphan disorder therapies / rare disorder therapies / manufacturing / therapies for Americans with rare disorders / therapies for those with rare disorders / therapies for rare disorders / therapy for a rare disease / / MedicalCondition each rare disorder / Rare Diseases / both rare disorders / rare disorder / less serious disease / chronic condition / disease / orphan disorders / Neglected Diseases / serious disease / rare disease / orphan disorder / different rare disorders / rare / serious diseases / rarest urea cycle disorder / NAGS deficiency / rare disorders / rare and neglected diseases / prevalent disease / AIDS / prevalent diseases / unique rare disorder / each particular rare disorder / disorders / / MedicalTreatment alternative therapy / investigational therapy / investigational therapies / / Organization National Institute of Health / NORD Task Force / NORD’s Corporate Council / Congress / Task Force / U.S. Food and Drug Administration / National Organization for Rare Disorders / Senate Appropriations Committee Agriculture Subcommittee / Center for Drug Evaluation and Research / Advisory Committee / / Person Frank Sasinowski / Francis Collins / Kessler / Jesse Goodman / Griebel / Janet Woodcock / John Crowley / / Position Director for Rare Diseases / leading advocate / player / Chair of the Board / official / CEO / Director / Commissioner / Chief Scientist and Deputy Commissioner / / Technology drug development / / SocialTag Pharmaceuticals policy Drug discovery Food and Drug Administration Therapeutics United States Public Health Service Orphan drug Orphan Drug Act Pharmaceutical industry Criticism of the Food and Drug Administration Pharmaceutical sciences